沪指8月18日上涨0.85%，申万所属行业中，今日上涨的有29个，涨幅居前的行业为通信、综合，涨幅 分别为4.46%、3.43%。医药生物行业今日上涨1.07%。跌幅居前的行业为房地产、石油石化，跌幅分别 为0.46%、0.10%。 资金面上看，两市主力资金全天净流出160.57亿元，今日有8个行业主力资金净流入，电子行业主力资 金净流入规模居首，该行业今日上涨2.48%，全天净流入资金50.40亿元，其次是通信行业，日涨幅为 4.46%，净流入资金为49.04亿元。 主力资金净流出的行业有23个，非银金融行业主力资金净流出规模居首，全天净流出资金70.87亿元， 其次是电力设备行业，净流出资金为50.90亿元，净流出资金较多的还有医药生物、基础化工、房地产 等行业。 医药生物行业今日上涨1.07%，全天主力资金净流出47.06亿元，该行业所属的个股共474只，今日上涨 的有347只，涨停的有7只;下跌的有119只。以资金流向数据进行统计，该行业资金净流入的个股有155 只，其中，净流入资金超亿元的有7只，净流入资金居首的是塞力医疗，今日净流入资金1.52亿元，紧 随其后的是福瑞股份、新天药业，净流入资金分别 ...

Group 1 - The core viewpoint of the news is that the medical consumables supply chain (SPD) sector experienced a rise of 1.45% on August 18, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3728.03, up 0.85%, while the Shenzhen Component Index closed at 11835.57, up 1.73% [1] - The trading volume and turnover for Saily Medical reached 409,100 shares and 1.187 billion yuan, with a closing price of 29.87 and a gain of 5.14% [1] Group 2 - The net inflow of main funds into the SPD sector was 117 million yuan, while retail funds saw a net outflow of 39.43 million yuan [2] - The table of individual stocks in the SPD sector shows various performance metrics, with Saily Medical and Dashi Intelligent being notable performers [2][3] - The main fund inflow for Saily Medical was 141.1 million yuan, accounting for 11.90% of the total, while retail funds showed a net outflow of 45.87 million yuan [3]

证券之星消息，8月18日AI医疗板块较上一交易日上涨1.59%，塞力医疗领涨。当日上证指数报收于 3728.03，上涨0.85%。深证成指报收于11835.57，上涨1.73%。AI医疗板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 29.87 | 5.14% | 40.91万 | 11.87亿 | | 300725 | 药石科技 | 49.92 | 4.33% | 24.24万 | 11.73亿 | | 688246 | 嘉和美康 | 36.72 | 3.15% | 5.10万 | 1.85亿 | | 300168 | 万达信息 | 8.23 | 3.13% | 51.09万 | 4.16亿 | | 300253 | 卫宁健康 | 10.70 | 2.79% | 116.23万 | 12.39亿 | | 688222 | 成都先导 | 23.03 | 2.54% | 23.20万 | 5.33亿 | | 603990 | 麦迪科技 | 15 ...

医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 5.14 | 21.42 | 15167.42 | | 300049 | 福瑞股份 | 20.00 | 8.88 | 14112.13 | | 002873 | 新天药业 | 10.04 | 21.73 | 12756.46 | | 300003 | 乐普医疗 | 7.50 | 5.21 | 11879.51 | | 600645 | 中源协和 | 5.87 | 7.07 | 10630.01 | | 300204 | 舒泰神 | 3.85 | 5.17 | 10605.35 | | 688189 | 南新制药 | 20.03 | 13.24 | 10160.34 | | 000538 | 云南白药 | 1.57 | 1.14 | 7852.22 | | 600557 | 康缘药业 | 2.15 | 5.69 | 7699.12 | | 002082 | 万邦德 | 10.01 | 3.49 | ...

Market Performance - The pharmaceutical commercial sector increased by 0.67% compared to the previous trading day, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3728.03, up 0.85%, while the Shenzhen Component Index closed at 11835.57, up 1.73% [1] Individual Stock Performance - Saily Medical (603716) closed at 29.87, up 5.14%, with a trading volume of 409,100 shares and a transaction value of 1.187 billion [1] - Yifeng Pharmacy (603939) closed at 23.87, up 2.14%, with a trading volume of 100,900 shares and a transaction value of 239 million [1] - Other notable performers include Yaoyigou (300937) at 30.10 (+2.03%), Laobaixing (603883) at 18.43 (+1.26%), and Haiwang Biological (000078) at 2.69 (+1.13%) [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 10.8635 million from institutional investors, while retail investors saw a net inflow of 12.0341 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Detailed Capital Flow for Selected Stocks - Saily Medical had a net outflow of 95.4222 million from institutional investors, while retail investors contributed a net inflow of 45.8725 million [3] - Guoyao Co. (600511) saw a net inflow of 38.7702 million from institutional investors, but a net outflow of 35.7166 million from retail investors [3] - Other stocks like Zhejiang Zhenyuan (000705) and Ruikang Pharmaceutical (002589) also showed varied capital flows, indicating differing investor sentiments across the sector [3]

金融界消息，根据中登公司数据显示，截至上周最后一个交易日（8月15日），塞力医疗股东质押比例 占总股本9.23%，位居两市第989位。 数据显示，塞力医疗股东共质押1930.00万股，分为5笔，其中无限售股1930.00万股，质押总市值5.48亿 元。 资料显示，塞力斯医疗科技集团股份有限公司的主营业务是体外诊断试剂、体外诊断仪器的销售业务。 公司的主要产品是单纯销售、集约化IVD、集约化SPD。公司较早将IVD集约化业务升级布局SPD运营 业务，取得先发优势。同时基于公司早些年强大的IVD运营根基，凭借医疗供应领域二十余年的经验累 积和过硬实力荣登中国物流与采购联合会医疗器械供应链50强获奖企业名单，同时被授予《医药产品医 院院内物流服务规范》团体标准试点单位。公司董事长为温伟，总经理为王政。 从股票走势来看，塞力医疗近一年上涨 319.65%。 来源：金融界 ...

Core Viewpoint - The company, Saily Medical, is actively developing digital therapies in the field of brain science, particularly focusing on mental health management through innovative software solutions and strategic collaborations with leading institutions and technology partners [1]. Group 1: Company Developments - As of August 15, 2025, Saily Medical's stock closed at 28.41 yuan, down 3.69%, with a turnover rate of 18.76% and a trading volume of 358,300 hands, resulting in a transaction amount of 1.017 billion yuan [1]. - The company has established a digital management software named "Haisi Lingxi" aimed at assisting in the management of major mental illnesses such as depression and bipolar disorder, leveraging AI and internet technologies [1]. - In April 2025, Saily Medical launched an AI diagnostic technology research center (TAIDxLab) in Shanghai, focusing on rapid molecular diagnostics for infections and critical conditions, as well as digital therapies for brain science [1]. Group 2: Strategic Collaborations - Saily Medical has partnered with Huawei Technologies and a key national laboratory to explore the application of brain science models in psychiatry, aiming to transition the industry from experience-driven to data-driven approaches [1]. - The collaboration with Zhejiang University First Affiliated Hospital's Mental Health Center is part of a national key project for the prevention and treatment of common mental disorders, which commenced in April 2024 [1]. - The partnership aims to build a closed-loop system for secure and reliable medical data processing, integrating resources from medical institutions, pharmaceutical companies, and regulatory bodies [1]. Group 3: Market Activity - On August 15, 2025, the net outflow of main funds from Saily Medical was 136 million yuan, accounting for 13.35% of the total transaction amount [2][3]. - Retail investors showed a net inflow of 147 million yuan, representing 14.49% of the total transaction amount, indicating strong interest from individual investors despite the outflow from institutional funds [3].

Group 1 - The stock price of Saily Medical (603716) closed at 28.41 yuan as of August 15, 2025, representing a 2.93% increase from the previous week's price of 27.6 yuan [1] - The highest intraday price reached 31.31 yuan on August 13, 2025, while the lowest intraday price was 27.55 yuan on August 11, 2025 [1] - The total market capitalization of Saily Medical is currently 5.427 billion yuan, ranking 18th out of 31 in the pharmaceutical commercial sector and 3060th out of 5152 in the A-share market [1] Group 2 - The actual controller of the company, Mr. Wen Wei, has completed the release of the pledge on 3,000,000 shares, reducing his pledged shares to 5,300,000, which is 55.01% of his holdings and 2.77% of the total share capital [1] - The cumulative pledged shares by the controlling shareholder, Saihai Technology, and Mr. Wen Wei amount to 19,300,000 shares, representing 61.71% of their total holdings and 10.10% of the total share capital [1] Group 3 - The convertible bond "Saily Convertible Bond" will pay interest on August 21, 2025, for the period from August 21, 2024, to August 20, 2025 [2] - The total issuance amount of the convertible bond is 543.31 million yuan, with an interest payment of 2.50 yuan per bond (including tax) [2] - The interest payment record date is August 20, 2025, with the ex-dividend date and payment date both set for August 21, 2025 [2]

Core Viewpoint - The company, Saily Medical, is actively engaging in the brain-computer interface industry, having developed a digital management software for mental health conditions, which aligns with national policies promoting this sector [1] Group 1: Product Development - Saily Medical has established a digital therapy system named "Haisi Lingxi" targeting major mental illnesses such as depression and bipolar disorder, leveraging AI and internet technologies [1] - The software serves as a tool for researchers, doctors, and patients, creating a knowledge graph for brain science and related research [1] Group 2: Strategic Collaborations - In April 2024, Saily Medical will collaborate with Zhejiang University First Affiliated Hospital's Mental Health Center on a national key project focusing on common mental disorders [1] - A strategic cooperation framework was signed in early 2025 with Huawei Technologies and a key laboratory team to explore the application of brain science models in psychiatry [1] Group 3: Infrastructure and Technology - The company has established an AI diagnostic technology research center (TAIDxLab) in Shanghai, focusing on rapid molecular diagnostics and digital therapies for brain science [1] - The center utilizes Huawei's AI infrastructure to efficiently process large volumes of data and aims to create a secure ecosystem involving medical institutions, pharmaceutical companies, and regulatory bodies [1]

Core Viewpoint - The company, Saily Medical (603716.SH), is actively investing in the field of digital therapies for brain science, focusing on mental health management through innovative technology and strategic partnerships [1] Group 1: Company Initiatives - In 2022, Saily Medical began its strategic layout in the digital therapy sector for brain science, leveraging its subsidiary, Haisitai Medical Technology Co., Ltd., to develop a comprehensive digital management system for mental illnesses [1] - The "Haisilingxi" system, developed in collaboration with Zhejiang University First Affiliated Hospital's Mental Health Center, targets major mental disorders such as depression and bipolar disorder [1] - A national key project under the "Brain Plan 2030" was initiated in April 2024, involving multi-center studies across 14 leading medical institutions [1] Group 2: Strategic Partnerships - In early 2025, Saily Medical signed a strategic cooperation framework with Huawei Technologies and Professor Hu Shaohua's team from the National Key Laboratory of Brain-Machine Intelligence to explore the application of brain science models in psychiatry [1] - The collaboration aims to transition the industry from experience-driven to data-driven approaches, utilizing Huawei's computational infrastructure and clinical data [1] Group 3: Technological Development - By April 2025, Saily Medical established an AI diagnostic technology research center (TAIDx Lab) in Shanghai, focusing on rapid molecular diagnostics for infections and critical conditions, as well as digital therapies for brain science [1] - The lab is equipped with Huawei's Ascend AI cluster and Kunpeng servers to efficiently process large volumes of data, creating a secure and closed-loop system involving medical institutions, pharmaceutical companies, and regulatory bodies [1] - Future efforts will concentrate on advancing technology development and application to build core competitive advantages through technological barriers [1]